Clinical trials: Prostate Cancer Stage
Prostate Cancer
A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer
Two groups of patients with prostate cancer will be enrolled: Group A: patients whose cancer has worsened or spread after being on hormonal therapy and has not had any chemotherapy.
- Trial name
- NCT00557037
- Testing
- Phenoxodiol
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- MEI Pharma, Inc.
Metastasis From Malignant Tumor of Prostate (Disorder)
Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer
This is a prospective, open-label Phase 2 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent metastatic prostate cancer after radical prostatectomy or radiation therapy.
- Trial name
- NCT05653856
- Testing
- 64Cu-PSMA I&T
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Curium US LLC
Prostate Cancer
Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)
The objective of this study is to evaluate the safety and efficacy of priming vaccinations, and subsequent boosting vaccinations with Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic…
- Trial name
- NCT00140387
- Testing
- Immunotherapy allogeneic GM-CSF secreting cellular vaccine
- Volunteers
- 20 people
- Sponsor
- Cell Genesys
Solid Tumor, Breast Cancer
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
This is a Phase 1 study intended to determine the MTD of OCT-598 following multiple-dose therapy and to establish the RP2D for OCT-598 as a single agent, by assessing its safety and tolerability as monotherapy and in combination…
- Conditions
- Solid Tumor, Breast Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT07358806
- Testing
- OCT-598, Docetaxel
- Where
- 3 sites in South Korea
- Volunteers
- 51 people
- Sponsor
- Oscotec Inc.
Metastatic Castration-Resistant Prostate Cancer Patients
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy
TSL2109 is a novel CDK4/6-DYRK2 dual-target inhibitor developed by Jiangsu Tasly Diyee Pharmaceutical Co., Ltd. for solid tumor treatment.
- Trial name
- NCT07514065
- Testing
- Treatment arm: TSL2109 capsules。Oral administration。
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Prostatic Neoplasms
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
The purpose of this study is to determine the safety of docetaxel and CNTO 328 when given together as a treatment. The second goal of this study is to determine if a combination of docetaxel and CNTO 328 has an effect on prostate…
- Trial name
- NCT00401765
- Testing
- CNTO 328, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Centocor, Inc.
Prostate Cancer
Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004071
- Testing
- leflunomide, mitoxantrone hydrochloride, prednisone
- Where
- 3 sites in United States
- Sponsor
- Pfizer
Prostate Cancer
Phase II, Dose Finding Study of GTx-758
The purpose of this study is to determine the appropriate loading and maintenance dose of GTx-758 to reach and maintain castration for the duration of the study.
- Trial name
- NCT01393119
- Testing
- GTx-758
- Where
- 21 sites in United States
- Volunteers
- 77 people
- Sponsor
- GTx
Prostatic Neoplasm
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
This Phase 1/2 study is intended to investigate the safety, tolerability, and radiation dosimetry of 177Lu-PSMA-R2 and further assess preliminary efficacy data in patients with metastatic castration-resistant prostate cancer…
- Trial name
- PROter (NCT03490838)
- Testing
- 177Lu-PSMA-R2
- Where
- 11 sites in United States, Spain
- Volunteers
- 27 people
- Sponsor
- Advanced Accelerator Applications
Prostate Cancer
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT00887198
- Testing
- Abiraterone acetate, Prednisone
- Where
- 134 sites in United States, Australia and 9 more
- Volunteers
- 1,088 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer
This is a clinical trial of orally administered Ruxolitinib (INCB018424) in patients whose disease has progressed following 1 prior chemotherapy regimen (not including anti-androgens or ketoconazole) for metastatic…
- Trial name
- NCT00638378
- Testing
- Ruxolitinib
- Where
- 15 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Corporation
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy…
- Conditions
- Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
- Trial name
- NCT04104776
- Testing
- Tulmimetostat, Enzalutamide
- Where
- 80 sites in United States, France and 5 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Given the activity of docetaxel in patients with progressive, metastatic castration-resistant prostate cancer, this study is being undertaken to evaluate the activity of tesetaxel, an orally bioavailable taxane, in…
- Trial name
- NCT01296243
- Testing
- Tesetaxel
- Where
- 4 sites in United States
- Volunteers
- 57 people
- Sponsor
- Genta Incorporated
Prostate Cancer
Phase II Laser Focal Therapy of Prostate Cancer
Target recruitment: 1000 subjects. The purpose of this research study is to continue to investigate the safety and effectiveness of using MR (magnetic resonance) guided laser focal therapy for prostate cancer and to evaluate…
- Trial name
- LITT or FLA (NCT02243033)
- Testing
- MR-guided laser focal therapy
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- HALO Diagnostics
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic…
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
- Trial name
- NCT05519449
- Testing
- JANX007, Darolutamide
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 272 people
- Sponsor
- Janux Therapeutics
Prostatic Neoplasms
Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
To determine if the addition of radium-223 dichloride to standard treatment is able to prolong life and to delay events specific for prostate cancer which has spread to the bone, such as painful fractures or bone pain which needs…
- Trial name
- ERA 223 (NCT02043678)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Abiraterone, Prednisone/Prednisolone
- Where
- 163 sites in United States, Australia and 17 more
- Volunteers
- 806 people
- Sponsor
- Bayer
Prostate Cancer
A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy
This is a single arm, open label study of up to 20 patients with prostate cancer scheduled for prostatectomy at the NIH Clinical Center.
- Trial name
- NCT01279785
- Testing
- 123I-MIP-1072
- Where
- United States
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Prostatic Neoplasms
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).
- Trial name
- NCT05022849
- Testing
- JNJ-75229414, Bridging Therapy
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Janssen Research & Development, LLC
High Risk Prostate Carcinoma
Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis
Only in subjects who satisfy the inclusion/exclusion criteria, a single dose of [F-18]Florastamin at 10 ± 1 mCi is IV administered at Visit 2, and [F-18]Florastamin PET/CT images are obtained from the head to thigh after 110 ± 10…
- Trial name
- NCT05004285
- Testing
- [F-18]Florastamin
- Where
- 5 sites in South Korea
- Volunteers
- 398 people
- Sponsor
- FutureChem
mCRPC
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
- Trial name
- TALAPRO-2 (NCT03395197)
- Testing
- Talazoparib with enzalutamide
- Where
- 370 sites in United States, Argentina and 24 more
- Volunteers
- 1,054 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.